• Halozyme Therapeutics average ebitda margin for 2023 was 49.28%, a 11.01% increase from 2022.
• Halozyme Therapeutics average ebitda margin for 2022 was 55.38%, a 15.53% decline from 2021.
• Halozyme Therapeutics average ebitda margin for 2021 was 65.56%, a 649.26% decline from 2020.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.